Pyrimidine derivatives with antitubercular activity.

Drug development Mycobacterium tuberculosis Pyrimidine Structure-activity relationships Tuberculosis

Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
15 Jan 2023
Historique:
received: 27 10 2022
revised: 17 11 2022
accepted: 18 11 2022
pubmed: 3 12 2022
medline: 4 1 2023
entrez: 2 12 2022
Statut: ppublish

Résumé

Small molecules with antitubercular activity containing the pyrimidine motif in their structure have gained more attention after three drugs, namely GSK 2556286 (GSK-286), TBA-7371 and SPR720, have entered clinical trials. This review provides an overview of recent advances in the hit-to-lead drug discovery studies of antitubercular pyrimidine-containing compounds with the aim to highlight their structural diversity. In the first part, the review discusses the pyrimidine compounds according to their targets, pinpointing the structure-activity relationships of each pyrimidine family. The second part of this review is concentrated on antitubercular pyrimidine derivatives with a yet unexplored or speculative target, dividing the compounds according to their structural types.

Identifiants

pubmed: 36459759
pii: S0223-5234(22)00848-0
doi: 10.1016/j.ejmech.2022.114946
pii:
doi:

Substances chimiques

Antitubercular Agents 0
Pyrimidines 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

114946

Informations de copyright

Copyright © 2022 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Vladimir Finger (V)

Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 50005 Hradec Kralove, Czech Republic; Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec, Kralove, Czech Republic.

Martin Kufa (M)

Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 50005 Hradec Kralove, Czech Republic; Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec, Kralove, Czech Republic.

Ondrej Soukup (O)

Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec, Kralove, Czech Republic.

Daniele Castagnolo (D)

Department of Chemistry, University College London, 20 Gordon Street, WC1H 0AJ, London, United Kingdom.

Jaroslav Roh (J)

Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 50005 Hradec Kralove, Czech Republic. Electronic address: jaroslav.roh@faf.cuni.cz.

Jan Korabecny (J)

Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec, Kralove, Czech Republic. Electronic address: jan.korabecny@fnhk.cz.

Articles similaires

Humans Chondrocytes Osteoarthritis Matrix Metalloproteinase 13 Drug Discovery
Tumor Microenvironment Nanoparticles Immunotherapy Cellular Senescence Animals
Testicular Neoplasms Neoplasms, Germ Cell and Embryonal Humans Cisplatin Jumonji Domain-Containing Histone Demethylases
Deep Learning RNA, Bacterial RNA, Small Untranslated Mycobacterium tuberculosis Computational Biology

Classifications MeSH